Latest 麻豆女优 Health News Stories
KHN鈥檚 鈥榃hat the Health?鈥: Boosting Confusion
Federal health officials appear poised to extend a recommendation for covid boosters to all adults, following moves by some governors and mayors to broaden the eligible booster pool as caseloads rise. Meanwhile, the Food and Drug Administration finally has a nominee to head the agency: former FDA chief Robert Califf. And Medicare premiums for consumers will likely rise substantially in 2022, partly due to the approval of a controversial drug to treat Alzheimer鈥檚 disease. Tami Luhby of CNN, Sarah Karlin-Smith of the Pink Sheet and Rachel Cohrs of Stat join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews Dan Weissmann, host of the 鈥淎n Arm and a Leg鈥 podcast.
KHN鈥檚 鈥榃hat the Health?鈥: Biden Social-Spending 鈥楩ramework鈥 Pulls Back on Key Health Pledges
President Joe Biden unveiled a compromise 鈥淏uild Back Better鈥 framework shortly before taking off for key meetings in Europe, but it鈥檚 unclear whether the framework can win the votes of all Democrats in the House and Senate, and it leaves out some of the party鈥檚 health priorities, notably significant provisions to lower prescription drug prices. Meanwhile, younger children may soon be eligible for covid vaccines. Joanne Kenen of Politico and Johns Hopkins, Sarah Karlin-Smith of the Pink Sheet and Rachana Pradhan of KHN join KHN鈥檚 Julie Rovner to discuss these issues and more.
KHN鈥檚 鈥榃hat the Health?鈥: Dems Agree to Agree, But Not on What to Agree On
Negotiations on the health parts of President Joe Biden鈥檚 domestic agenda are getting serious but have yet to produce a deal every Democrat can support. Meanwhile, the Food and Drug Administration remains without a nominated leader but manages to take the first steps toward approving over-the-counter hearing aids. Joanne Kenen of Politico and Johns Hopkins, Tami Luhby of CNN and Rachel Cohrs of Stat join KHN鈥檚 Julie Rovner to discuss these issues and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read too.
Watch: Going Beyond the Script of ‘Dopesick’ and America’s Real-Life Opioid Crisis
KHN teamed up with Hulu for a discussion of America’s opioid crisis, following the Oct. 13 premiere of the online streaming service鈥檚 new series 鈥淒opesick.鈥
KHN鈥檚 鈥榃hat the Health?鈥: The Politics of Vaccine Mandates
Like almost everything else associated with the covid-19 pandemic, partisans are taking sides over whether vaccines should be mandated. Meanwhile, Democrats on Capitol Hill are still struggling to find compromise in their effort to expand health insurance and other social programs. Alice Miranda Ollstein of Politico, Jen Haberkorn of the Los Angeles Times and Mary Ellen McIntire of CQ Roll Call join KHN鈥檚 Julie Rovner to discuss these issues and more. Also this week, Rovner interviews best-selling author Beth Macy about her book 鈥淒opesick,鈥 and the new Hulu miniseries based on it.
Journalists Drill Down on Covid Vaccine Boosters, Misinformation Online
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
Alzheimer鈥檚 Drug Targets People With Mild Cognitive Impairment. What Does That Mean?
The condition can be an early signal of Alzheimer鈥檚 disease, but not always. Other health concerns could be causing thinking or memory problems, and the new drug, Aduhelm, would not be appropriate for those patients.
Who Qualifies for a Covid Booster? The List Is Growing Longer
KHN鈥檚 Sarah Jane Tribble and Arthur Allen join Science Friday host Ira Flatow to recap the evolving news in the run-up to offering booster shots for the covid vaccine.
From the FDA’s Empty Seat to Chock-Full ICUs, Journalists Recap the Week’s Stories
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
KHN鈥檚 鈥榃hat the Health?鈥: The Autumn of Democrats鈥 Discontent
Congress is back in session with a short time to finish a long to-do list, including keeping the government operating and paying its bills. Hanging in the balance is President Joe Biden鈥檚 entire domestic agenda, including major changes proposed for Medicare, Medicaid and the Affordable Care Act. Meanwhile, the new Texas abortion law that bans the procedure early in pregnancy is prompting action in Washington. Joanne Kenen of Politico, Mary Ellen McIntire of CQ Roll Call and Sarah Karlin-Smith of the Pink Sheet join KHN鈥檚 Julie Rovner to discuss these issues and more. Also, Rovner interviews former FDA Commissioner Scott Gottlieb about his new book on the covid-19 pandemic.
Biosimilar Drugs Are Cheaper Than Biologics. Are They Similar Enough to Switch?
Biologic drugs, made from living organisms, and the cheaper biosimilar drugs that mimic them are more complex than chemical drugs and their generic counterparts. The Food and Drug Administration says biosimilars are as safe and effective as the biologics, and doctors agree 鈥 but they are cautious about changing the treatment regimen of patients doing well.
Public Health Experts 鈥楩labbergasted鈥 That Biden Still Hasn鈥檛 Picked an FDA Chief
The Food and Drug Administration has been mired in controversies related to drug approvals and covid vaccines, all without a permanent leader.
How Fauci and the NIH Got Ahead of the FDA and CDC in Backing Boosters
With real-time data streaming in from highly specialized researchers in the U.S. and abroad, NIH scientists became convinced that boosting the covid-19 vaccine was needed to save lives, prompting the president to announce a plan with a Sept. 20 start date. Scientists at the regulatory agencies weren鈥檛 yet convinced. A meeting Friday will determine what happens next. Here鈥檚 the story from behind the scenes.
Journalists Give Rundown on Vaccine Mandates and FDA’s Official Approval of the Pfizer Shot
KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here鈥檚 a collection of their appearances.
KHN鈥檚 鈥榃hat the Health?鈥: Vaccine Approval Moves the Needle on Covid
The FDA鈥檚 formal approval of the first vaccine to prevent covid-19 may or may not prompt doubters to go out and get shots, but it has clearly prompted employers to make vaccination a work requirement. Meanwhile, moderates and liberals in the U.S. House put aside their differences long enough to keep a giant social-spending bill on track, at least for now. Joanne Kenen of Politico, Tami Luhby of CNN and Sarah Karlin-Smith of the Pink Sheet join KHN鈥檚 Julie Rovner to discuss these issues and more. Plus, for 鈥渆xtra credit,鈥 the panelists suggest their favorite health policy stories of the week they think you should read, too.
Apple, Bose and Others Pump Up the Volume on Hearing Aid Options, Filling Void Left by FDA
A 2017 law designed to help lower the cost of hearing aids mandated that federal officials set rules for a new class of devices consumers could buy without needing to see an audiologist. But those regulations are still on hold.
Lo que debes saber sobre el refuerzo de la vacuna contra covid
La administraci贸n de Biden anunci贸 el mi茅rcoles 18 de agosto planes para ofrecer refuerzos de la vacuna contra covid-19 a todos los adultos estadounidenses a partir del pr贸ximo mes.
The White House Says Boosters for All. Here鈥檚 What You Need to Know.
Federal officials are preparing to offer those who received Pfizer or Moderna covid vaccines a third dose in September. But the FDA and CDC are still reviewing the data for final clearance.
鈥楾ainted鈥 Blood: Covid Skeptics Request Blood Transfusions From Unvaccinated Donors
In another twist on covid vaccine hesitancy, blood centers say they are starting to hear from transfusion patients demanding blood from unvaccinated donors. Experts say the option is neither practical nor medically justifiable.
Mensaje del CEO de Pfizer al p煤blico: conf铆en en nosotros con el refuerzo de la vacuna contra covid
Pfizer anunci贸 su ensayo global de fase 3 sobre una tercera dosis a mediados de julio. La fecha de finalizaci贸n de ese ensayo es en 2022. Los resultados de la fase 3 suelen ser necesarios antes de la aprobaci贸n oficial.
